SG Hiscock appoints new investment analyst


MEDIA RELEASE: Melbourne-based boutique fund manager SG Hiscock & Company has appointed Sophie Smith in the role of investment analyst.

Ms Smith will join the emerging companies’ business unit, which incorporates the recently launched SGH Medical Technology Fund, with a remit of company research, modelling and valuation work, and performance attribution.

Ms Smith will directly report into portfolio manager, Rory Hunter, who said strong investor demand has driven the need for growing the capabilities of the Fund.

“The domestic medical technology sector is growing exponentially. Sophie will work with the portfolio management team as they look to identify the most exciting opportunities in the industry, with a focus on high-quality growth companies.

“As demand for diagnostic testing and healthcare services grows, we expect to see governments continue to incentivise innovation in the industry, resulting in fertile ground for emerging medical technology investment opportunities.

“We’re anticipating strong demand in the space for some time, and to have Sophie on board so soon after inception of the Fund is an exciting development for our clients,” he said.

Ms Smith has recently completed a Bachelor of Commerce at Melbourne University with High Distinction, majoring in finance and economics.

The SGH Medical Technology Fund invests in a mix of established and start-up medical technology companies, listed and unlisted, in Australia and New Zealand, and typically holds between 40 and 60 investments. It has a focus on social impact and aims to provide investors with long-term capital growth.

SG Hiscock & Co will establish a registered charitable foundation which will be funded by 10 per cent of net revenue from the Fund, including performance fees.

Get in touch

Speak with us now to find out how we can help you

Send a message